Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Open access

Abstract

Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient strategy to treat melanoma harboring BRAF-mutation. The development of acquired resistance is inevitable due to the signaling pathway rewiring. Combining western blotting, immunohistochemistry, and reverse phase protein array (RPPA), we aim to understanding the role of the mTORC1 signaling pathway, a center node of intracellular signaling network, in mediating drug resistance of BRAF-mutant melanoma to the combination of BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) therapy. The mTORC1 signaling pathway is initially suppressed by BRAFi and MEKi combination in melanoma but rebounds overtime after tumors acquire resistance to the combination therapy (CR) as assayed in cultured cells and PDX models. In vitro experiments showed that a subset of CR melanoma cells was sensitive to mTORC1 inhibition. The mTOR inhibitors, rapamycin and NVP-BEZ235, induced cell cycle arrest and apoptosis in CR cell lines. As a proof-of-principle, we demonstrated that rapamycin and NVP-BEZ235 treatment reduced tumor growth in CR xenograft models. Mechanistically, AKT or ERK contributes to the activation of mTORC1 in CR cells, depending on PTEN status of these cells. Our study reveals that mTOR activation is essential for drug resistance of melanoma to MAPK inhibitors, and provides insight into the rewiring of the signaling networks in CR melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41388-021-01911-5

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Research works printed but not linked: 1

  1. Libutti S, Garcia-Carbonero R, Wolin EM, Custodio A, Yao JC, Hendifar AE, et al. CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET). Neuroendocrinology. 2015;102:131–131.

Cited by

See all 66

Metadata

Authors
Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., Randell, S., Beroard, A., Sugarman, E., Rebecca, V. W., Wei, Z., Lu, Y., Mills, G. B., Field, J., Villanueva, J., Xu, X., Herlyn, M., & Guo, W.
Affiliations
  • University of Pennsylvania (US)
  • The Wistar Institute (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Mount Sinai Hospital (CA)
  • New Jersey Institute of Technology (US)
  • Oregon Health & Science University (US)
Corresponding author
  • Herlyn, Meenhard
  • Guo, Wei
Venue
Oncogene
Published
2021-07-24
Volume
40
Issue
37
Pages
5590-5599
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W3183839551
Cited by
66
References
88
Citations by year
2026: 14 · 2025: 11 · 2024: 11 · 2023: 13 · 2022: 14 · 2021: 3
FWCI
3.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Oncogene (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM141832)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 CA114046, P50 CA174523, U54 CA224070)
  • U.S. Department of Defense (DoD - PRCRP WX1XWH-16-1-0119 [CA150619])
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
mTORC1 signaling, acquired drug resistance, BRAF-mutant melanoma, BRAF inhibitors, MEK inhibitors, MAPK signaling, rapamycin, NVP-BEZ235, Akt, ERK, PTEN, combination therapy resistance
MeSH terms
Mechanistic Target of Rapamycin Complex 1, MTOR Inhibitors, Animals, Humans, Imidazoles, Melanoma, Mutation, Quinolines, Signal Transduction, Apoptosis, Drug Resistance, Neoplasm, Sirolimus, Mitogen-Activated Protein Kinase Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. https://app.cochat.ai/papers/10.1038/s41388-021-01911-5
The paper
Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., Randell, S., Beroard, A., Sugarman, E., Rebecca, V. W., Wei, Z., Lu, Y., Mills, G. B., Field, J., Villanueva, J., . . . Guo, W. (2021). Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. https://doi.org/10.1038/s41388-021-01911-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.